Matinas Biopharma Holdings, Inc. (MTNB) vs Valion Bio, Inc. (VBIO)

Matinas Biopharma Holdings, Inc. and Valion Bio, Inc. are both Biotechnology companies. Matinas Biopharma Holdings, Inc. and Valion Bio, Inc. are of similar size ($2.4M and $2.4M). Matinas Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 2,139.4% against −49.6%. Across the 15 metrics below, Matinas Biopharma Holdings, Inc. leads on 12 and Valion Bio, Inc. on 3.

Valuation

Metric MTNB VBIO Biotechnology median
P/E n/m n/m 8.50
P/S 0.24 0.33 9.71
P/B 0.56 0.04 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.05 11.28 9.21
Earnings yield (348.48%) (15,509.47%) (33.15%)
Free cash flow yield (602.45%) (9,619.81%) (25.50%)

Profitability

Metric MTNB VBIO Biotechnology median
Gross margin 0.00% (58.09%) 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (154.28%) (489.30%) (56.36%)
Return on assets (98.53%) (104.96%) (48.04%)
Return on invested capital (419.27%) (61.01%) 0.00%

Growth

Metric MTNB VBIO Biotechnology median
Revenue growth (TTM) 2,139.41% (49.63%) 6.02%
EPS growth (last fiscal year) 62.08% 60.16% 30.26%
Revenue growth, 5-year CAGR 55.69% 13.18% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MTNB VBIO Biotechnology median
Debt to equity 0.00 0.62 0.00
Current ratio 0.85 1.11 4.72
Net debt to EBITDA 0.62 0.79 0.96

Dividend

Metric MTNB VBIO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MTNB VBIO Biotechnology median
Market cap 2.37m 2.39m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack